Blueprint Medicines Competitors, Revenue, Alternatives and Pricing

Claim your profile


Boston, MA USA
Total Funding:$259.8M
Lead Investor(s):Goldman Sachs & Co. LLC, Morgan Stanley

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Blueprint Medicines's estimated annual revenue is currently $445M per year.
  • Blueprint Medicines received $345.0M in venture funding in March 2019.
  • Blueprint Medicines's estimated revenue per employee is $973,742
  • Blueprint Medicines's total funding is $259.8M.

Employee Data

  • Blueprint Medicines has 457 Employees.
  • Blueprint Medicines grew their employee count by 27% last year.
  • Blueprint Medicines currently has 33 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Ohana Bioscienc...
Compass Therape...
Cell Signaling ...
Momenta Pharmac...
Hamilton Storag...
Alnylam Pharmac...
Missing a competitor? Contribute!?

Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients lives. We don't think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







Executive Contacts

Timothy LabrancheSenior Director, Toxicologic Pathology
Scott MulhollandManager, Regulatory Affairs
Angela PontrelloDirector, Quality Control
Tuan SiVice President, Pharmacovigilance & Safety
Michael NestAssociate DirectorEmail Available
Roan MartinSenior Director, Quality AssuranceEmail Available
Todd BilletDirector, Field Operations
Lauren BarnesSenior Vice President, Market Access
Teresa Alvarez-DiezAssociate Director
Marta MurciaDirector, Strategic Alliances

Blueprint Medicines News

09/03/2019 - Why Is Blueprint Medicines (BPMC) Down 18.3% Since Last Earnings Report?

A month has gone by since the last earnings report for Blueprint Medicines (BPMC). Shares have lost about 18.3% in that time frame, ...

09/08/2019 - 5,495 Shares in Blueprint Medicines Corp (NASDAQ:BPMC) Purchased by WCM Investment Management LLC

WCM Investment Management LLC purchased a new stake in shares of Blueprint Medicines Corp (NASDAQ:BPMC) in the second quarter, ...

09/03/2019 - Hull MA Hits 77.57162963 for Blueprint Medicines Corporation (NASDAQ:BPMC)

Traders following shares of Blueprint Medicines Corporation (NASDAQ:BPMC) may have noted that the stock most recently closed at 76.51.

Blueprint Medicines Funding

DateAmountRoundLead InvestorsReference
2014-01-08$25.0MBNextech Invest LtdArticle
2014-11-13$50.0MCPartner Fund ManagementArticle
2016-12-07$143.8MUndisclosedGoldman, Sachs & CoArticle
2016-12-14$134.5MUndisclosedGoldman, Sachs & Co.Article
2017-03-30$230.0MUndisclosedGoldman, Sachs & CoArticle
2017-04-05$215.6MUndisclosedGoldman, Sachs & CoArticle
2017-12-12$316.2MUndisclosedGoldman Sachs & Co. LLCArticle
2017-12-14$345.0MUndisclosedGoldman Sachs & Co. LLCArticle
2019-03-28$345.0MUndisclosedGoldman Sachs & Co. LLCArticle

Blueprint Medicines Executive Hires

2012-11-14Daniel S. LynchChairmanArticle
2013-09-18Kyle KuvalankaChief Business OfficerArticle
2014-07-25Jeffrey AlbersCEOArticle
2015-02-12Anthony BoralSVP Clinical DevelopmentArticle
2016-09-07Tracey McCainChief Legal Officer/EVPArticle
2016-11-15Marion DorschChief Scientific OfficerArticle
2017-10-11Christopher MurraySVP Technical OperationsArticle
2018-10-30Christina RossiChief Commercial OfficerArticle